GenSight Biologics S.A. Profile Avatar - Palmy Investing

GenSight Biologics S.A.

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its pr…

Biotechnology
FR, Paris [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 28% Weak
Profitability n.A. n.A.
Fin. Growth 83% Positive
Leverage & Liquidity 17% Weak
Per Share Metrics 0% Bad
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q1 Q2 Δ in %
EV/EBITDA 10.73 -11.55 -12.93
Graham Fair Price 0.00 0.49 0.49
PEG inf 0.00 0.04
Price/Book 19.70 -1.07 -1.34
Price/Cash Flow 19.70 -7.25 -9.03
Prices/Earnings 19.70 -2.28 -2.84
Price/Sales -19.70 30.84 38.41
Price/FCF 19.70 -7.25 -9.03
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q1 Q2 Δ in %
Gross Profit Margin 0.00 1.00 1.00
Operating Margin 0.00 -4.28 -4.28
ROA 0.00 -0.20 -0.20
ROE 0.12 0.12 0.00
ROIC 1.03 1.03 0.00
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q1 Q2 Δ in %
Debt QOQ 0.07 0.15 -55.59
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ 0.41 0.00 inf
EPS QOQ 0.75 0.00 inf
FCF QOQ 0.13 0.00 inf
Revenue QOQ 5.97 0.00 inf
Naive Interpretation member
03 - Financial Growth · Positive
Fundamentals

Leverage & Liquidity

Metric Q1 Q2 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 0.00 0.00 0.00
Days Sales Outstanding (DSO) 3.65 3.65 0.00
Inventory Turnover 0.00 0.00 0.00
Debt/Capitalization -5.91 -5.91 0.00
Quick Ratio 0.71 0.77 8.78
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q1 Q2 Δ in %
Book Value -0.30 -0.30 0.00
Cash 0.08 0.08 0.00
Capex < 0.005 < 0.005 0.00
Free Cash Flow -0.04 -0.04 0.00
Revenue 0.01 0.01 0.00
Naive Interpretation member
05 - Per Share Metrics · Bad
Fundamentals

Financial Health

Metric Q1 Q2 Δ in %
Current Ratio 0.77 0.77 0.00
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -3.90 -4.29 -10.07
Naive Interpretation Member
06 - Financial Health · Bad
End of SIGHT.PA's Analysis
CIK: - CUSIP: F4374K117 ISIN: FR0013183985 LEI: - UEI: -
Secondary Listings
SIGHT.PA has no secondary listings inside our databases.